• Neotiv

  Participated · Series A · Nov 2022

  Neotiv’s core product, neotivCare, is a CE class I medical device digital-health app that delivers structured memory tests aimed at people with subjective cognitive decline. The software is designed to help relatives encourage medical visits and to assist clinicians in determining whether cognitive deterioration qualifies as mild cognitive impairment. Neotiv says its tools can help pick up Alzheimer’s earlier, supporting earlier access to care and potentially better outcomes as treatments emerge. The company was founded in 2017 as a spinout from Otto von Guericke University Magdeburg and maintains a scientific advisory board with experts from the German Center for Neurodegenerative Diseases, UCL and UC Berkeley. Neotiv plans to use fresh funding to grow German customer adoption, expand internationally, and deliver further software innovations. The article cites global disease estimates (about 32 million Alzheimer’s patients and a further 69 million in a prodromal phase) as the addressable need the company aims to serve. Neotiv develops mobile apps that measure the psychological effects of Alzheimer’s disease at early stages using memory tests validated in national and international scientific studies. The tests produce scores that indicate whether specific brain regions are functionally compromised, delivering a snapshot of a patient’s mental capacity and enabling long‑term, high‑frequency memory monitoring. That monitoring is intended to enable dynamic tailoring of preventative and therapeutic measures and to help health‑conscious individuals optimize lifestyle changes to reduce dementia risk. The apps are designed for private users, clinicians and drug developers, allowing doctors to detect changes and monitor treatment courses. Drug developers can use the app to improve pre‑selection of trial candidates and to obtain higher‑frequency monitoring of treatment effects. The company is led by CEO Dr. Chris Rehse and dementia researcher Prof. Emrah Düzel and recently secured seed funding from High‑Tech Gründerfonds (amount undisclosed) to support product launch and development.

• Lemonaid Health

  Participated · Series A · May 2017

  Lemonaid Health is an on-demand platform connecting patients with U.S.-licensed doctors and nurse practitioners for consultation through treatment nationwide. The company provides care for conditions including anxiety and depression, UTIs, birth control, hair loss, hypothyroidism, erectile dysfunction, genital herpes and sinus infections, and offers free, fast delivery of prescription medications. Its proprietary technology platform integrates clinical algorithms and decision-support tools with clinician care, and it follows evidence-based guidelines and updated clinical protocols to deliver quality care at lower cost. Led by co-founder and CEO Paul Johnson, Lemonaid operates as an independent healthcare provider. The company plans to use new funding to expand its team of medical professionals and broaden services to include treatment for asthma, hypertension, Type 2 diabetes and additional mental-health services. Financially, the company has raised a total of $55M to date, including the recent Series B. Lemonaid Health operates a custom-built telehealth platform that leverages evidence-based guidelines and up-to-date clinical protocols to provide care for conditions such as acid reflux, erectile dysfunction, flu, hair loss, UTIs and birth control. Board-certified doctors evaluate patients and, when appropriate, recommend treatments and send prescriptions to the pharmacy of choice. The service is accessible from any modern web browser and via iOS and Android apps, and is available in 14 states. Led by Paul Johnson, the company intends to use new funds to continue innovating in online healthcare and to expand its operating footprint. The company recently completed an $11m Series A financing to support those plans. Icebreaker Health operates a telemedicine platform with a strong emphasis on security and HIPAA compliance. Its platform includes data encrypted at the file level, 24/7 monitoring and patching, HITECH-certified servers for HIPAA, penetration testing, and an intrusion detection system. The company also offers automated log monitoring and documented HIPAA risk assessments specific to every project, and maintains technology E&O and data privacy insurance. The business is led by Paul Johnson and Ian Van Every. In August 2015 the company raised $6.6M in funding, with an initial SEC filing target of $6.87M. That offering was supported by 24 unknown/undisclosed investors.

No current team members are available.